|
1
|
Chiba-Falek O, Lopez GJ and Nussbaum RL:
Levels of alpha-synuclein mRNA in sporadic Parkinson disease
patients. Mov Disord. 21:1703–1708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singleton AB, Farrer M, Johnson J,
Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra
A, Nussbaum R, et al: alpha-Synuclein locus triplication causes
Parkinson's disease. Science. 302:8412002. View Article : Google Scholar
|
|
3
|
Galtrey CM and Fawcett JW: The role of
chondroitin sulfate proteoglycans in regeneration and plasticity in
the central nervous system. Brain Res Rev. 54:1–18. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Purushothaman A, Fukuda J, Mizumoto S, ten
Dam GB, van Kuppevelt TH, Kitagawa H, Mikami T and Sugahara K:
Functions of chondroitin sulfate/dermatan sulfate chains in brain
development. Critical roles of E and iE disaccharide units
recognized by a single chain antibody GD3G7. J Biol Chem.
282:19442–19452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okamoto M, Mori S, Ichimura M and Endo H:
Chondroitin sulfate proteoglycans protect cultured rat's cortical
and hippocampal neurons from delayed cell death induced by
excitatory amino acids. Neurosci Lett. 172:51–54. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato Y, Nakanishi K, Tokita Y, Kakizawa H,
Ida M, Maeda H, Matsui F, Aono S, Saito A, Kuroda Y, et al: A
highly sulfated chondroitin sulfate preparation, CS-E, prevents
excitatory amino acid-induced neuronal cell death. J Neurochem.
104:1565–1576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cañas N, Valero T, Villarroya M, Montell
E, Vergés J, García AG and López MG: Chondroitin sulfate protects
SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1
via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther.
323:946–953. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ju C, Hou L, Sun F, Zhang L, Zhang Z, Gao
H, Wang L, Wang D, Lv Y and Zhao X: Anti-oxidation and
antiapoptotic effects of chondroitin sulfate on
6-hydroxydopamine-induced injury through the up-regulation of nrf2
and inhibition of mitochondria-mediated pathway. Neurochem Res.
40:1509–1519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McLaughlin RW, De Stigter JK, Sikkink LA,
Baden EM and Ramirez-Alvarado M: The effects of sodium sulfate,
glycosaminoglycans, and Congo red on the structure, stability, and
amyloid formation of an immunoglobulin light-chain protein. Protein
Sci. 15:1710–1722. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Q, Li J, Liu C, Song C, Li P, Yin F,
Xiao Y, Li J, Jiang W, Zong A, et al: Protective effects of low
molecular weight chondroitin sulfate on amyloid beta (Aβ)-induced
damage in vitro and in vivo. Neuroscience. 305:169–182. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woods AG, Cribbs DH, Whittemore ER and
Cotman CW: Heparan sulfate and chondroitin sulfate
glycosaminoglycan attenuate beta-amyloid(25–35) induced
neurodegeneration in cultured hippocampal neurons. Brain Res.
697:53–62. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chartier-Harlin MC, Kachergus J, Roumier
C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J,
Hulihan M, et al: Alpha-synuclein locus duplication as a cause of
familial Parkinson's disease. Lancet. 364:1167–1169. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paumier KL, Rizzo SJ Sukoff, Berger Z,
Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W,
et al: Behavioral characterization of A53T mice reveals early and
late stage deficits related to Parkinson's disease. PLoS One.
8:e702742013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chesselet MF: In vivo alpha-synuclein
overexpression in rodents: A useful model of Parkinson's disease?
Exp Neurol. 209:22–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lashuel HA and Hirling H: Rescuing
defective vesicular trafficking protects against alpha-synuclein
toxicity in cellular and animal models of Parkinson's disease. ACS
Chem Biol. 1:420–424. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Periquet M, Fulga T, Myllykangas L,
Schlossmacher MG and Feany MB: Aggregated alpha-synuclein mediates
dopaminergic neurotoxicity in vivo. J Neurosci. 27:3338–3346. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saha AR, Ninkina NN, Hanger DP, Anderton
BH, Davies AM and Buchman VL: Induction of neuronal death by
alpha-synuclein. Eur J Neurosci. 12:3073–3077. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu LJ, Sagara Y, Arroyo A, Rockenstein E,
Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M and Masliah E:
alpha-synuclein promotes mitochondrial deficit and oxidative
stress. Am J Pathol. 157:401–410. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parihar MS, Parihar A, Fujita M, Hashimoto
M and Ghafourifar P: Mitochondrial association of alpha-synuclein
causes oxidative stress. Cell Mol Life Sci. 65:1272–1284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parihar MS, Parihar A, Fujita M, Hashimoto
M and Ghafourifar P: Alpha-synuclein overexpression and aggregation
exacerbates impairment of mitochondrial functions by augmenting
oxidative stress in human neuroblastoma cells. Int J Biochem Cell
Biol. 41:2015–2024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin LJ, Semenkow S, Hanaford A and Wong
M: Mitochondrial permeability transition pore regulates Parkinson's
disease development in mutant α-synuclein transgenic mice.
Neurobiol Aging. 35:1132–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Anderson JP, Walker DE, Goldstein JM, de
Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee
M, et al: Phosphorylation of Ser-129 is the dominant pathological
modification of alpha-synuclein in familial and sporadic Lewy body
disease. J Biol Chem. 281:29739–29752. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujiwara H, Hasegawa M, Dohmae N,
Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K and Iwatsubo
T: alpha-Synuclein is phosphorylated in synucleinopathy lesions.
Nat Cell Biol. 4:160–164. 2002.PubMed/NCBI
|
|
24
|
Sugeno N, Takeda A, Hasegawa T, Kobayashi
M, Kikuchi A, Mori F, Wakabayashi K and Itoyama Y: Serine 129
phosphorylation of alpha-synuclein induces unfolded protein
response-mediated cell death. Biol Chem. 283:23179–23188. 2008.
View Article : Google Scholar
|
|
25
|
Sato H, Arawaka S, Hara S, Fukushima S,
Koga K, Koyama S and Kato T: Authentically phosphorylated
α-synuclein at Ser129 accelerates neurodegeneration in a rat model
of familial Parkinson's disease. J Neurosci. 31:16884–16894. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oliveras-Salvá M, Van der Perren A,
Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C and
Baekelandt V: rAAV2/7 vector-mediated overexpression of
alpha-synuclein in mouse substantia nigra induces protein
aggregation and progressive dose-dependent neurodegeneration. Mol
Neurodegener. 8:442013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dias V, Junn E and Mouradian MM: The role
of oxidative stress in Parkinson's disease. J Parkinsons Dis.
3:461–491. 2013.PubMed/NCBI
|
|
28
|
Junn E and Mouradian MM: Human
alpha-synuclein over-expression increases intracellular reactive
oxygen species levels and susceptibility to dopamine. Neurosci
Lett. 320:146–150. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Devi L, Raghavendran V, Prabhu BM,
Avadhani NG and Anandatheerthavarada HK: Mitochondrial import and
accumulation of alpha-synuclein impair complex I in human
dopaminergic neuronal cultures and Parkinson disease brain. J Biol
Chem. 283:9089–9100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chinta SJ, Mallajosyula JK, Rane A and
Andersen JK: Mitochondrial α-synuclein accumulation impairs complex
I function in dopaminergic neurons and results in increased
mitophagy in vivo. Neurosci Lett. 486:235–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Y, Duan C, Lü L, Gao H, Zhao C, Yu S,
Uéda K, Chan P and Yang H: α-Synuclein overexpression impairs
mitochondrial function by associating with adenylate translocator.
Int J Biochem Cell Biol. 43:732–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seo JH, Rah JC, Choi SH, Shin JK, Min K,
Kim HS, Park CH, Kim S, Kim EM, Lee SH, et al: α-synuclein
regulates neuronal survival via Bcl-2 family expression and PI3/Akt
kinase pathway. FASEB J. 16:1826–1828. 2002.PubMed/NCBI
|
|
33
|
Yuan Y, Jin J, Yang B, Zhang W, Hu J,
Zhang Y and Chen NH: Overexpressed alpha-synuclein regulated the
nuclear factor-kappaB signal pathway. Cell Mol Neurobiol. 28:21–33.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niture SK, Kaspar JW, Shen J and Jaiswal
AK: Nrf2 signaling and cell survival. Toxicol Appl Pharmacol.
244:37–42. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hwang YP and Jeong HG: Mechanism of
phytoestrogen puerarin-mediated cytoprotection following oxidative
injury: Estrogen receptor-dependent up-regulation of PI3K/Akt and
HO-1. Toxicol Appl Pharmacol. 233:371–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
